Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin versus capecitabine in previously treated locally advanced or metastatic breast cancer
ACTRN12607000176460Phase 3Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Eribulin with Capecitabine (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Sep 2006; status: recruiting.
02
Drugs
eribulincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000176460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000176460.